A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
BACKGROUND
Moxifloxacin, a fluoroquinolone, has demonstrated its safety and effectiveness in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis.


OBJECTIVE
The aim of this article was to provide a synthesis and critical appraisal of economic evaluations of the management of respiratory tract infections with moxifloxacin.


METHODS
Studies were included if they assessed the costs and consequences of moxifloxacin as compared with an alternative antimicrobial in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis.


CONCLUSIONS
Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis with moxifloxacin is equally or more effective and less expensive than treatment with other antimicrobials.
Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Onderwijs en Navorsing 2, Herestraat 49, PO Box 521, 3000 Leuven, Belgium. steven.simoens@pharm.kuleuven.be
Steven
S
Simoens
Marc
M
Decramer
D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D001372:Aza Compounds / Q000191:economics* / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy; D017714:Community-Acquired Infections / Q000188:drug therapy; D003365:Costs and Cost Analysis; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011804:Quinolines / Q000191:economics* / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin